Antidepressant use during pregnancy and the risk of pregnancy-induced hypertension

British Journal of Clinical Pharmacology

Volumn 74, Issue 2, 2012, Pages 362-369

  De Vera, Mary A ^a,b   Bérard, Anick ^a,b  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b UNIVERSITY OF MONTREAL   (Canada)

Author keywords

Antidepressants; Pharmacoepidemiology; Pregnancy; Pregnancy induced hypertension

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; ANTIINFECTIVE AGENT; CITALOPRAM; CLOMIPRAMINE; DESIPRAMINE; DOPAMINE UPTAKE INHIBITOR; DOXEPIN; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; MONOAMINE OXIDASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; NORADRENALIN UPTAKE INHIBITOR; NORTRIPTYLINE; PAROXETINE; SERTRALINE; TETRACYCLIC ANTIDEPRESSANT AGENT; TRIMIPRAMINE; VENLAFAXINE;

ADULT; ANXIETY; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; DRUG EXPOSURE; DRUG USE; FEMALE; FIRST TRIMESTER PREGNANCY; GESTATIONAL AGE; GYNECOLOGIST; HEALTH CARE UTILIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MATERNAL HYPERTENSION; PREECLAMPSIA; PREGNANCY; PRESCRIPTION; PRIORITY JOURNAL; PSYCHIATRIST; PUERPERAL DEPRESSION; SENSITIVITY ANALYSIS;

ADULT; ANTIDEPRESSIVE AGENTS; CASE-CONTROL STUDIES; FEMALE; HUMANS; HYPERTENSION, PREGNANCY-INDUCED; LOGISTIC MODELS; MULTIVARIATE ANALYSIS; ODDS RATIO; PAROXETINE; PREGNANCY; PREGNANCY COMPLICATIONS; PROSPECTIVE STUDIES; QUEBEC; REGISTRIES; RISK ASSESSMENT; RISK FACTORS; SEROTONIN UPTAKE INHIBITORS; YOUNG ADULT;

EID: 84863763480     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2012.04196.x     Document Type: Article

References (31)

1. Bennett H, Einarson A, Taddio A, Koren G, Einarson T. Prevalence of depression during pregnancy: systematic review. Obstet Gynecol 2004; 103: 698-709.
2. Bennett H, Einarson A, Taddio A, Koren G, Einarson T. Depression during pregnancy: overview of clinical factors. Clin Drug Investig 2004; 24: 157-79.
3. Nakhai-Pour H, Broy P, Bérard A. Use of antidepressants during pregnancy and the risk of spontaneous abortion. Can Med Assoc J 2010; 182: 1031-7.
4. Ramos E, St-Andre M, Berard A. Association between antidepressant use during pregnancy and infants born small for gestational age. Can J Psychiatry 2010; 55: 643-52.
5. Ramos E, St-Andre M, Rey E, Oraichi D, Berard A. Duration of antidepressant use during pregnancy and risk of major congenital malformations. Br J Psychiatry 2008; 192: 344-50.
6. Berard A, Ramos E, Rey E, Blais L, St-Andre M, Oraichi D. First trimester exposure to paroxetine and risk of cardiac malformations in infants: the importance of dosage. Birth Defects Res B Dev Reprod Toxicol 2007; 80: 18-27.
7. Bolte A, van Geijn H, Dekker G. Pathophysiology of preeclampsia and the role of serotonin. Eur J Obstet Gynecol 2001; 95: 12-21.
8. Thase ME. Effects of venlafaxine on blood pressure: a meta-analysis of original data from 3744 depressed patients. J Clin Psychiatry 1998; 59: 502-8.
9. Toh S, Mitchell A, Louik C, Werler M, Chambers C, Hernández-Diaz S. Selective serotonin reuptake inhibitor use and risk of gestational hypertension. Am J Psychiatry 2009; 166: 320-8.
10. Reis M, Källén B. Delivery outcome after maternal use of antidepressant drugs in pregnancy: an update using Swedish data. Psychol Med 2010; 40: 1723-33.
11. Berard A, Lacasse A. Validity of perinatal pharmacoepidemiologic studies using data from the RAMQ administrative database. Can J Clin Pharmacol 2009; 16: e360-9.
12. World Health Organization. International Classification of Diseases, Ninth Revision. Geneva: World Health Organization, 1997.
13. Tamblyn R, Lavoie G, Petrella L, Monette J. The use of prescription claims databases in pharmacoepidemiological research: the accuracy and comprehensiveness of the prescription claims database in Quebec. J Clin Epidemiol 1995; 48: 999-1009.
14. Levy AR, Mayo NE, Grimard G. Rates of transcervical and pertrochanteric hip fractures in the province of Quebec, Canada, 1981-1992. Am J Epidemiol 1995; 142: 428-36.
15. Roy E, Haley N, Leclerc P, Sochanski B, Boudreau J-F, Boivin J-F. Mortality in a cohort of street youth in Montreal. J Am Med Assoc 2004; 292: 569-74.
16. Magee L, Helewa M, Moutquin J, von Dadelszen P. Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy. J Obstet Gynaecol Can 2008; 30: S9-15.
17. Essebag V, Genest J Jr, Suissa S, Pilote L. The nested case-control study in cardiology. Am Heart J 2003; 146: 581-90.
18. Bryson C, Ioannou G, Rulyak S, Critchlow C. Association between gestational diabetes and pregnancy-induced hypertension. Am J Epidemiol 2003; 158: 1148-53.
19. Ros H, Cnattingius S, Lipworth L. Comparison of risk factors for preeclampsia and gestational hypertension in a population-based cohort study. Am J Epidemiol 1998; 147: 1062-70.
20. Ramos E, Oraichi D, Rey E, Blais L, Berard A. Prevalence and predictors of antidepressant use in a cohort of pregnant women. BJOG 2007; 114: 1055-64.
21. Toh S, Mitchell AA, Werler MM, Hernandez-Diaz S. Sensitivity and specificity of computerized algorithms to classify gestational periods in the absence of information on date of conception. Am J Epidemiol 2008; 167: 633-40.
22. Van Nueten J. Serotonin and the blood vessel wall. J Cardiovasc Pharmacol 1985; 7: (Suppl. 7): S49-51.
23. Ortiz J, Artigas F. Effects of monoamine uptake inhibitors on extracellular and platelet 5-hydroxytryptamine in rat blood: different effects of clomipramine and fluoxetine. Br J Pharmacol 1992; 105: 941-6.
24. Skop BP, Brown TM. Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors. Psychosomatics 1996; 37: 12-6.
25. Finkel MS, Laghrissi-Thode F, Pollock BG, Rong J. Paroxetine is a novel nitric oxide synthase inhibitor. Psychopharmacol Bull 1996; 32: 653-8.
26. 2, and hyaluronic acid production in human synovial cells and synovial tissue cultures. Arthritis Rheum 1999; 42: 2561-8.
27. Kurki T, Hiilesmaa V, Raitasalo R, Mattila H, Ylikorkala O. Depression and anxiety in early pregnancy and risk for preeclampsia. Obstet Gynecol 2000; 95: 487-90.
28. Qiu C, Sanchez S, Lam N, Garcia P, Williams M. Associations of depression and depressive symptoms with preeclampsia: results from a Peruvian case-control study. BMC Womens Health 2007; 7: 1-7.
29. Berard A, Nakhai-Pour H, Kulaga S. Impact of missing data on potential confounders in perinatal pharmacoepidemiologic studies using administrative databases. Can J Clin Pharmacol 2009; 16: e202-33.
30. Suissa S, Garbe E. Primer: administrative health databases in observational studies of drug effects - advantages and disadvantages. Nat Clin Pract Rheumatol 2007; 3: 725-32.
31. De Jong van den Berg LT, Feenstra N, Sorensen HT, Cornel MC. Improvement of drug exposure data in a registration of congenital anomalies. Pilot-study: pharmacist and mother as sources for drug exposure data during pregnancy. EuroMAP Group. Europen Medicine and Pregnancy Group. Teratology 1999; 60: 33-6.